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Abstract: Background: Accumulation of misfolded proteins is a common hallmark of several 
neurodegenerative disorders (NDs) which results from a failure or an impairment of the protein 
quality control (PQC) system. The PQC system is composed by chaperones and the degradative 
systems (proteasome and autophagy). Mutant proteins that misfold are potentially neurotoxic, thus 
strategies aimed at preventing their aggregation or at enhancing their clearance are emerging as 
interesting therapeutic targets for NDs. Methods: We tested the natural alkaloid berberine (BBR) 
and some derivatives for their capability to enhance misfolded protein clearance in cell models of 
NDs, evaluating which degradative pathway mediates their action. Results: We found that both 
BBR and its semisynthetic derivatives promote degradation of mutant androgen receptor 
(ARpolyQ) causative of spinal and bulbar muscular atrophy, acting mainly via proteasome and 
preventing ARpolyQ aggregation. Overlapping effects were observed on other misfolded proteins 
causative of amyotrophic lateral sclerosis, frontotemporal-lobar degeneration or Huntington 
disease, but with selective and specific action against each different mutant protein. Conclusions: 
BBR and its analogues induce the clearance of misfolded proteins responsible for NDs, representing 
potential therapeutic tools to counteract these fatal disorders. 
Keywords: misfolding; neurodegeneration; spinal and bulbar muscular atrophy; protein 
aggregation; berberine; amyotrophic lateral sclerosis; frontotemporal dementia; autophagy; 
proteasome 
 
1. Introduction 
Protein homeostasis (proteostasis) ensures proteome integrity and its proper regulation is 
essential for cell health and survival. The maintenance of proteostasis involves protein folding and 
degradation via a tight control mediated by the protein quality control (PQC) system. The PQC 
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system requires the coordinated action of chaperones and degradative systems, namely the 
ubiquitin–proteasome system (UPS) and the autophagic-lysosomal pathway (ALP) [1,2]. UPS is 
involved in the fast protein degradation. Instead, ALP is responsible for clearing long-lived proteins, 
physically aggregated proteins and organelles [3]. 
When proteostasis is unbalanced, e.g., with ageing, the PQC system becomes unable to remove 
all the aberrant intracellular proteins efficiently, and some misfolded proteins might escape from 
intracellular defence. These events are worsened by genetic mutations, post-translation modifications 
or proteolytic cleavage that might confer misfolded conformations to the proteins, increasing their 
propensity to aggregate [4–7]. Protein misfolding and aggregation are common hallmarks of several 
neurodegenerative diseases (NDs), because neurons are postmitotic cells highly susceptible to the 
intracellular accumulation of damaged and misfolded proteins. Among these diseases, the most 
common are Parkinson’s disease (PD), Alzheimer’s disease (AD), the class of polyglutamine (polyQ) 
diseases, amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), etc. [8]. 
Moreover, PQC system activity declines with aging and this might contribute to the adult-onset of 
NDs [9,10]. 
PolyQ diseases are a group of NDs caused by an abnormal polyQ expansion in causative and 
unrelated proteins. To date, nine polyQ diseases have been identified: spinal and bulbar muscular 
atrophy (SBMA), Huntington’s disease (HD), dentatorubral pallidoluysian atrophy (DRPLA), and six 
forms of spinocerebellar ataxia (SCAs) [11]. The polyQ size has a critical threshold specific for each 
disease that must be exceeded for disease onset. The size of the stretch is inversely correlated with 
the age of onset and symptoms severity [12]. SBMA is a rare X-linked neuromuscular disorder caused 
by polyQ expansion in the androgen receptor (AR), leading to a selective motoneuron degeneration 
occurring in the brainstem and spinal cord [13,14]. In SBMA only males are affected, and it has been 
estimated that there is a prevalence of 1:30,000 male inhabitants, even though the founder effect may 
account for geographical area variations [15,16]. SBMA is characterized by tremor, cramps and 
muscle weakness causing difficulties in walking, speaking or swallowing [17]. Signs of testicular 
atrophy, gynecomastia and reduced fertility may also be present [18,19]. All these clinical signs can 
be explained by an altered function of the mutant ARpolyQ in SBMA. In fact, the AR protein belongs 
to the steroid hormone nuclear receptor family and mediates the action of male androgens 
(testosterone (T) and dihydrotestosterone (DHT)) which regulate sexual male differentiation and 
other important biological functions such as the anabolic actions in skeletal muscle, and neuronal 
plasticity and neuroprotection in the central nervous system (CNS) [20–22]. ARpolyQ partially loses 
its transcriptional activity if compared to wild-type (wt) AR and this accounts for the endocrine signs 
identified in SBMA. However, complete androgen insensitivity syndrome, in which AR is completely 
inactive, does not result in neuronal loss suggesting that SBMA may be due to a gain of neurotoxic 
function of the mutant ARpolyQ. In fact, AR is highly expressed in the lower motoneurons and 
brainstem, as well as in the skeletal muscle, which are primary sites of SBMA pathogenesis [23]. The 
binding of androgens to AR normally induces conformational changes in the protein to allow its 
nuclear translocation, dimerization and interaction with specific DNA sequences [20]. In SBMA, the 
presence of the aberrantly long polyQ tract in AR may prevent its capability to reach the proper 
conformation after androgen activation, and the binding of androgens to ARpolyQ may induce its 
misfolding. It is important to note that the presence of the polyQ tract in AR protein is thought to 
induce structural alteration preventing its correct folding, possibly also altering the normal 
posttranslational modifications to which the wtAR undergoes right after its interaction with the 
ligand. Therefore, it is likely that the elongated polyQ in the mutant AR induces alteration on its 
intracellular trafficking and function. In addition, the exposure of the polyQ after ligand-induced 
Heat Shock Protein (HSP) dissociation causes protein misfolding which increases the propensity of 
the AR protein to aggregate. Misfolded ARpolyQ is poorly cleared from cells and may aggregate and 
perturb cells by inducing proteotoxic effects in affected motoneurons or muscle cells [24–28]. Thus, 
an enhanced ARpolyQ clearance should be beneficial against its neurotoxic properties. 
The mechanism of protein misfolding found in SBMA has been also related to HD and other 
polyQ diseases, since they share the same type of mutation found in ARpolyQ even if present in other 
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different proteins. HD is due to a polyQ expansion in the huntingtin (HTT) [29] a protein involved in 
embryogenesis and required for adult brain functions [30], being a scaffold protein implicated in a 
wide range of intracellular pathways, such as ALP, nuclear import, transcriptional regulation, 
apoptotic signaling and axonal transport [31–33]. 
In addition, SBMA also shares similarities with ALS, another motoneuron disease characterized 
by loss of upper and lower motoneurons causing progressive weakness and atrophy of skeletal 
muscles. ALS and SBMA involve the same cells types (with the exception of upper motor neurons 
spared in SBMA) and show similar symptoms [34–36]. However, only 10% of ALS cases are familial 
(fALS), while 90% of cases are sporadic (sALS). Some genes causing fALS, might also contribute to 
sALS [37]. Cu/Zn superoxide dismutase 1 (SOD1) gene mutations account for about 20% fALS, but 
misfolded wtSOD1 may also cause sALS [38,39]. TAR DNA-binding protein 43 (TDP-43) encoded by 
the TARDBP gene, is an RNA-binding protein found to accumulate into cytoplasmic inclusions in 
almost all sALS cases. The inclusions contain full length (FL) TDP-43, and some C-terminal fragments 
of TDP-43 (TDP-25 or TDP-35), generated by proteolytic cleavage by caspases or calpains [40]; the C-
terminus of TDP-43 is poorly structured and highly prone to aggregate when released from the FL 
protein and by mislocalizing into the cytoplasm may seed for aggregate formation. 
Despite the diverse aetiologies and the specific proteins involved, these NDs thus share a 
plethora of common characteristics and events that contribute to pathogenesis [41]; this may allow a 
possible common therapeutic approach aimed at stabilizing the native protein conformation, 
counteracting protein aggregation, or improving the misfolded protein clearance [34,35,42,43]. 
Several natural compounds, extracted from plants, are capable to regulate the PQC system and to 
exert protective effects in NDs [44]. An interesting compound is berberine (BBR), an isoquinoline 
alkaloid isolated from plants of Berberidaceae family, but also present in Papaveraceae and 
Ranunculaceae families. BBR is widely used in traditional Chinese medicine, and it has been shown to 
have a variety of pharmacological effects to attenuate inflammation, metabolic disorders, lipid 
metabolism, cardiovascular diseases, and it has been suggested to interfere with specific forms of 
cancer [45–51]. BBR has also been tested in in vitro, and in vivo models of AD, PD, HD, ALS/FTLD, 
where the compound was found to exert some neuroprotective effects [52–57]. Despite these findings, 
the mechanism of action of BBR remains poorly understood. Several intracellular mechanisms have 
been demonstrated to mediate the protective effects of BBR in neurons. The RAC-alpha 
serine/threonine-protein kinase (AKT) pathway and its downstream signaling such as apoptosis 
regulator BCL2 (BCL2), nuclear factor-kappaB (NF-kB), glycogen synthase kinase 3 beta (GSK3B), 
and mechanistic target of rapamycin kinase (MTOR) seem to be the principal mediators in promoting 
BBR effects against apoptosis, inflammation, oxidative stress and protein clearance in NDs [52,58–
62]. BBR is able to cross the blood brain barrier (BBB), but it is poorly absorbed and rapidly 
metabolized [63–68]. Here, we studied the effects of BBR and BBR-derived NAX014, NAX035 and 
NAX117 (NAXs) on the aggregation and clearance of the ARpolyQ responsible for SBMA, and we 
also extended this evaluation on the clearance of misfolded proteins responsible for SBMA-related 
NDs. NAX014 presents a 4-chlorophenyl moiety and an ethylenic linker, whereas NAX035 and 
NAX117 a benzhydryl and a 4,4-dimethoxybenzhydryl moieties, respectively. NAXs were selected 
from a proprietary class of BBR semisynthetic structural analogues [U.S. Pat. 8188,109B2 to 
Naxospharma s.r.l.], characterized by the presence of (hetero)aromatic moieties, bonded to the 13-
position of the parent alkaloid skeleton through a linker of variable length, in order to enhance the 
propensity for additional noncovalent aromatic interactions on the cellular target site(s) [69–74]. This 
could result in different biophysical effects with respect to the parent BBR and, hopefully, in a better 
biological outcome. 
2. Results 
2.1. Effects of BBR on ARpolyQ Clearance 
To analyze the intracellular kinetics of wtAR and AR polyQ in NSC34 cell line, we used a 
chimeric protein coding for Green Fluorescent Protein (GFP) fused with wt AR (GFP-AR.Q22) or 
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ARpolyQ (GFP-AR.Q48). These plasmid constructs were already tested and routinely used by us and 
other, and retain normal AR binding to androgens, nuclear translocation rate and proper 
transcriptional activity; in addition, the chimeric constructs showed the same biological behaviour 
and aggregation propensity of their related untagged plasmids [27,75–77]. In NSC34 cells, we 
observed that the wtAR is able to shuttle from cytoplasm to nucleus in response to the binding with 
the ligand testosterone. Otherwise, the mutant GFP-AR.Q48 is localized into the cytoplasm in its 
inactive status, but testosterone treatment induced the protein misfolding and the subsequent protein 
aggregation into the cytosol, confirming that SBMA is a ligand-dependent disorder (Figure 1A). In 
fact, ARpolyQ aggregation and neurotoxicity depend upon its testosterone activation, which also 
stabilizes the AR protein. This represents the situation found in patients, in which the high levels of 
testosterone in males activate ARpolyQ and trigger several intracellular pathways that contribute to 
disease pathogenesis. We initially assessed the specificity of the antibody both in Western Blot (WB) 
analysis and filter retardation assay (FRA) by using NSC34 cells expressing the exogenous 
recombinant AR with an elongated tract of 46 glutamines (AR.Q46) compared to a mock-transfected 
sample used as negative control. In microscopy analyses, to avoid cell permeabilization and 
immunoreaction with anti-AR antibody, which could give some unspecific autofluorescence signal 
in NSC34 cells, we selected a GFP-tagged mutant AR (GFP-AR.Q48) which also recapitulates the 
SBMA model without altering protein structure and function, since so far no differences have been 
reported between polyQ of such similar size (two Glns). Conversely, we demonstrated that both in 
WB and in FRA, the AR-H280 antibody was highly specific, since it detects only the band related to 
exogenous AR.Q46, while no signal is present in negative control samples, the untransfected NSC34 
cells, which are known to be devoid of endogenous AR. Therefore, the selected antibody is highly 
specific for the AR proteins. In FRA experiments on the same samples, we confirmed that testosterone 
treatment enhanced AR.Q46 protein accumulation of high-molecular-weight species (Figure 1B). 
Moreover, in this case, no signals were detectable in cells devoid of endogenous AR, confirming that 
all immunoreactive materials retained on the cellulose acetate membrane have to be ascribed to 
aggregated forms of AR.Q46. To determine the optimal dose of BBR, the NSC34 cells were treated 
with BBR at a 0.2–10 μM concentration range for 48 h and cell viability was measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The data indicate that BBR 
reduced cell viability starting from the dose of 0.5 μM, and this reduction was significant in a dose-
dependent manner up to 10 μM BBR in comparison to control group. No significant difference was 
observed in cell viability at dose of 0.2 μM BBR, which resulted in being well tolerated by NSC34 cells 
(Figure 1C). Thus, we selected this dose of BBR to perform all further analyses in a cellular model of 
SBMA. 
Treating NSC34 cells expressing AR.Q46 with BBR (used at three different nontoxic doses: 0.05–
0.1–0.2 μM), we observed BBR induced the clearance of monomeric AR.Q46 species (Figure 1D), and, 
in parallel, reduced the accumulation of AR.Q46 insoluble species in a dose-dependent manner (this 
reduction was significant at BBR treatment of 0.1–0.2 μM (Figure 1E)). Of note, BBR also was able to 
enhance the clearance of the unactivated AR.Q46 evaluated in WB, which provides an estimation of 
the whole amount of Sodium dodecyl sulfate (SDS)-soluble protein in the samples; this suggests that 
even this form of the receptor, which is not fully folded yet, may undergo to a BBR-regulated 
enhanced degradation. 
Since the effects of BBR could be exerted both/either at the level of protein translation and/or 
clearance, we used cycloheximide (CHX, a protein synthesis inhibitor) to test whether BBR acts on 
ARpolyQ synthesis and degradation. To this purpose, NSC34 cells expressing AR.Q46 were 
pretreated for one hour with CHX and then with BBR. In these conditions, we observed that BBR was 
still able to further reduce AR.Q46 levels in presence of CHX indicating that BBR prevents AR.Q46 
accumulation and aggregation by promoting its degradation (Figure 2A,B for quantification). 
To confirm this hypothesis, and to understand the main proteolytic pathway involved in BBR 
mechanism of action, we used inhibitors that selectively block the activity of UPS or ALP. We 
observed that the prodegradative activity of BBR on AR.Q46 was not affected by the autophagy 
inhibitor 3-methyladenine (3-MA). In fact BBR action on AR.Q46 clearance was not significant 
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counteracted by ALP inhibition with 3-MA (Figure 2C,D). Conversely, we observed that BBR-
mediated clearance of AR.Q46 was counteracted by the UPS selective inhibitor MG132, as shown by 
WB and FRA analysis (Figure 2E,F), suggesting that the BBR prodegradative activity on ARpolyQ is 
specifically mediated by the UPS activity. 
 
Figure 1. BBR reduced the ARpolyQ protein level. (A) Representative confocal microscopy analysis 
of GFP-AR.Q(n) intracellular localization. NSC34 cells were transfected with GFP-ARQ.22 or GFP-
AR.Q48 in absence or in presence of 10 nM testosterone. Nuclei were stained with DAPI (63X 
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magnification). Scale bar: 10 μM. (B) WB analysis performed on NSC34 cells transfected with AR.Q46 
in absence or in presence of 10 nM testosterone, untransfected control was added to test the antibody 
specificity. GAPDH was used as loading control. (C) MTT cell viability assay was performed on 
NSC34 cells treated with BBR at different concentration for 48 h (* p < 0.05, *** p < 0.001, one-way 
ANOVA, followed by Tukey’s test). (D,E) NSC34 cells were transfected with AR.Q46 in absence or 
presence of 10 nM testosterone and BBR at three different doses (0.05, 0.1, and 0.2 μM for 48 h Ethanol 
and DMSO were used as vehicle control for testosterone and BBR, respectively. (D) WB analysis was 
performed. GAPDH was used as loading control, and the bar graph represents the mean optical 
density ± SD of AR: GAPDH (n = 3) (E) FRA was performed, the bar graph represents the mean optical 
density of AR ± SD (n = 3). (* p < 0.05, ** p < 0.01, *** p < 0.001, two-way ANOVA, followed by Tukey’s 
test). 
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Figure 2. BBR pro-degradative activity on ARpolyQ. (A) WB analysis on NSC34 cells transfected with 
AR.Q46 in absence or in presence of 10 nM testosterone. To inhibit protein synthesis the cells were 
pretreated with 20μcycloheximide (CHX) and then treated with 0.2 μBBR or DMSO as vehicle 
control for 48 h. GAPDH was used as loading control. (B) The bar graph represents the mean optical 
density ± SD of AR: GAPDH (n = 3) (* p < 0.05, *** p < 0.001, two-way ANOVA, followed by Tukey’s 
test). (C,F) NSC34 cells transfected with AR.Q46 in absence or in presence of 10 nM testosterone and 
treated with 0.2 μBBR and with 10 mM 3-MA (C,D) or 10μMG132 (E,F) to inhibit autophagic or 
proteasomal activity, respectively. (C,E) WB analyses were performed; GAPDH was used as loading 
control; the bar graphs represent the mean optical density ± SD of AR: GAPDH (n = 3). *** p < 0.001, 
two-way ANOVA, followed by Tukey’s test). (D,F) FRA was performed. The bar graphs represent 
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the mean optical density of AR ± SD (n = 3). (* p < 0.05, ** p < 0.01, *** p < 0.001, two-way ANOVA, 
followed by Tukey’s test). 
2.2. Effects of BBR-Derived Compounds on ARpolyQ Clearance 
To evaluate the potential toxicity of NAX014, NAX035 and NAX117 (the molecular structures of 
NAX compounds are illustrated in the Supplementary S1A) on immortalized motoneurons, cell 
viability assays were initially performed using MTT analysis on NSC34 cells treated with NAXs at 
the same range of BBR doses, as described above. We observed that neither NAX014 nor NAX035 
affected cell viability at a dose of 0.2 μM (Supplementary S1B and S1C), while NAX117 was even 
better tolerated even using higher doses than the other two NAX compounds (Supplementary S1D). 
Based on these data, we selected different concentrations of NAXs: 0.2 μM for NAX014 and NAX035, 
0.5 μM for NAX117. 
We tested the effects of NAXs on ARpolyQ clearance in comparison to BBR. As shown in the 
WB (Figure 3A) and FRA (Figure 3B) analyses, we observed that only NAX014 treatment significantly 
reduced AR.Q46 protein levels and aggregate accumulation, and this effect was similar to that exerted 
by BBR. NA0X35 and NAX117 induced only a slight and nonsignificant decrease in AR.Q46 
accumulation (Figure 3A,B.). Fluorescence microscopy analysis on cells transfected with the GFP-
AR.Q48 and treated with testosterone together with BBR or NAXs revealed that all these compounds 
were able to reduce the percentage of cells bearing GFP-positive aggregates of GFP-AR.Q48, 
indicating that the three compounds are able to reduce or counteract ARpolyQ aggregation (Figure 
3C and quantification in Figure 3D). 
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Figure 3. Effects of NAXs on ARpolyQ. (A,B) NSC34 cells were transfected with AR.Q46 in absence 
or in presence of 10 nM of testosterone and treated with BBR or NAX compounds for 48 h (BBR, 
NAX014 and NAX035 were used at 0.2 μM, NAX117 was used at 0.5 μM). (A) WB analysis was 
performed, GAPDH was used as loading control, the bar graph represents the mean optical density 
± SD of AR: GAPDH (n = 3) (* p < 0.05, ** p < 0.01, two-way ANOVA, followed by Tukey’s test). (B) 
FRA was performed. The bar graph represents the mean optical density of AR ± SD (n = 3) (* p < 0.05, 
** p < 0.01, *** p < 0.001, two-way ANOVA, followed by Tukey’s test). (C,D) Fluorescence microscope 
analysis performed on NSC34 cells transfected with GFP-ARQ48 in absence or in presence of 10 nM 
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testosterone and treated BBR or NAX compounds for 48 h (BBR, NAX014 and NAX035 were used at 
0.2 μM, NAX117 was used at 0.5 μM). (C) Representative fluorescence microscopy analysis of GFP-
AR.Q48 protein levels. Nuclei were stained with DAPI (63X magnification). Scale bar: 10 μM. (D) The 
quantification of GFP-AR.Q48 aggregates was performed using a PL 10X/20 eyepiece with graticules. 
The percentage of cells with aggregates was obtained dividing the number of cells with aggregates 
with the total number of GFP positive cells (* p < 0.05, ** p < 0.01, *** p < 0.001, two-way ANOVA, 
followed by Tukey’s test). 
2.3. Effects of BBR and BBR-Derived Compounds on Misfolded Proteins Involved in ALS and HD 
Since both BBR and the NAXs were found to be active on the mutant ARpolyQ activated by 
testosterone, we wondered whether these compounds were selective for this receptor or, instead, if 
they might exert a wider activity also against other misfolded proteins, thus possibly involved in a 
panregulation of the clearance of aggregating proteins in neurons. To this purpose, we also tested the 
activity of NAXs on three other mutant proteins or disease-associated protein fragments that are 
involved in ALS, FTLD and HD. 
Firstly, we decided to test BBR and NAXs in cellular models of ALS and FTLD. To this end, we 
used NSC34 cells expressing genes coding for the Cu/Zn superoxide dismutase 1 (SOD1) with a 
missense mutation in position 93 (SOD1-G93A) as a fALS model, and for the C-terminal TDP-43 
fragment of 25 KDa fused with the GFP (GFP-TDP-25) as a model for sALS and FTLD. 
The data have shown that BBR only slightly reduces SOD1-G93A soluble and insoluble species, 
whereas all the NAXs robustly enhanced the clearance of mutant SOD1-G93A measured both in WB 
(SDS-soluble species) and in FRA (high-molecular-weight aggregated species of this misfolded 
protein). Interestingly, endogenous SOD1 levels were not affected by BBR or NAX treatment (Figure 
4A,B). 
By analyzing the BBR effects on the sALS model based on immortalized motoneurons, we found 
that this compound was able to induce GFP-TDP-25 clearance, both by reducing its immunoreactive 
protein in WB (SDS-soluble species) and the accumulation of high-molecular-weight aggregated 
species measured in FRA. These effects of BBR on GFP-TDP-25 also confirmed previous data reported 
by Chang, et al. [54]. By analyzing the effects of the BBR-derived NAXs, we found that only NAX014 
was able to significantly reduce the overall amounts of TDP-25 high-molecular-weight aggregated 
species measured in FRA, while both NAX014 and NAX117 reduced the levels of SDS-soluble GFP-
TDP-25 in WB (Figure 4C,D). 
Since the mutant ARpolyQ toxicity strictly depends upon the elongated polyQ tract, which is 
also the stretch responsible for neurotoxicity exerted by the mutant HTT in HD, we next wanted to 
find out whether BBR and the NAXs were also active in this different form of ND. In particular, the 
toxicity of the HTT protein containing the polyQ tract has been mainly associated with the release of 
a caspase-3 cleaved N-terminal fragment (coded by exon1) or with its generation via an incomplete 
splicing [78,79]. For this reason, NSC34 cells were transfected with a plasmid coding for the related 
N-terminus of the HTT protein (carrying 73 glutamines, HTT-exon1-73Q). Although its therapeutic 
effect was already demonstrated in an HD animal model [55], in our cell model, BBR did not show 
significant effects on the clearance of the mutant HTT, both at levels of the SDS-soluble species 
(evaluated in WB, Figure 4E) and of the high-molecular-weight aggregated species (evaluated in 
FRA, Figure 4F). Surprisingly, no effects of NAXs were observed on HTT-exon1-73Q insoluble 
species, except for the NAX035, which reduced the accumulation of high-molecular-weight 
aggregated species of HTT-exon1-73Q (evaluated in FRA) (Figure 4E,F). 
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Figure 4. Effects of NAXs on misfolded proteins involved in ALS and HD. (A,B) NSC34 cells were 
transfected with plasmids coding for SOD1-G93A and treated BBR or NAX compounds for 48 h (BBR, 
NAX014 and NAX035 were used at 0.2 μM, NAX117 was used at 0.5 μM). (A) WB analysis was 
performed with anti-SOD1 antibody to detect exogenous human SO1-G93A and the endogenous 
murine SOD1 (mSOD1). GAPDH was used as loading control, the bar graph represents the mean 
optical density ± SD of SOD1-G93A: GAPDH (n = 3) (* p < 0.05, ** p < 0.01, one-way ANOVA, followed 
by Tukey’s test). (B) FRA was performed, the bar graph represents the mean optical density of SOD1-
G93A ± SD (n = 3) (* p < 0.05, *** p < 0.001, one-way ANOVA, followed by Tukey’s test). (C,D) NSC34 
cells were transfected with plasmids coding for GFP-TDP-25 and treated with BBR or NAX 
compounds for 48 h (BBR, NAX014 and NAX035 were used at 0.2 μM, NAX117 was used at 0.5 μM). 
(C) WB analysis was performed with anti-GFP antibody to detect the GFP-TDP-25. GAPDH was used 
as loading control, the bar graph represents the mean optical density ± SD of GFP-TDP-25: GAPDH 
(n = 3) (* p < 0.05, one-way ANOVA, followed by Tukey’s test). (D) FRA was performed, the bar graph 
represents the mean optical density of GFP-TDP-25 ± SD (n = 3) (* p < 0.05, followed by Tukey’s test). 
(E,F) NSC34 cells were transfected with plasmids coding for HTT-exon1-73Q and treated BBR or NAX 
compounds for 48 h (BBR, NAX014 and NAX035 were used at 0.2 μM, NAX117 was used at 0.5 μM). 
(E) WB analysis was performed with anti-HTT antibody to detect exogenous HTT-exon1-73Q. 
GAPDH was used as loading control, the bar graph represents the mean optical density ± SD of HTT-
exon1-73Q: GAPDH (n = 3) (one-way ANOVA, followed by Tukey’s test). (B) FRA was performed, 
the bar graph represents the mean optical density of HTT-exon1-73Q ± SD (n = 3) (* p < 0.05, one-way 
ANOVA, followed by Tukey’s test). 
3. Discussion 
In this study we analyzed how BBR and some semisynthetic derivatives of BBR enhance the 
clearance of misfolded proteins associated to three different NDs, possibly providing a new method 
of intervention to counteract these diseases. Here, we assayed BBR activity in a cellular model of 
SBMA targeting the mutant ARpolyQ that exerts neurotoxic activities in motoneurons causing the 
disease. Our data suggest that BBR enhances the degradation of mutant and misfolded ARpolyQ via 
the UPS, while ALP blockage does not counteract ARpolyQ clearance induced by BBR. These data 
are in line with a previous report showing that BBR is able to suppress wtAR signaling via UPS 
activity in prostate cancer [80]. Despite the present work, the detailed mechanism of action of BBR on 
ARpolyQ has not been clarified, a protein-specific activity of BBR on AR might be involved, since, in 
prostate cancer, BBR was shown to disrupt the interaction between AR and HSP90, the chaperone 
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involved in folding and degradation of AR [81], and protective in SBMA models [82–86]. These 
aspects may be particularly relevant for ARpolyQ, since it is known that HSP90, in cooperation with 
other chaperones, such as HSP70, maintains the AR (and its mutant ARpolyQ) in an inactive status 
confined into the cell cytoplasm, and only after ligand binding, HSPs are released and the AR 
migrates into the nucleus to exert its transcriptional regulation on androgen-dependent genes. In the 
case of ARpolyQ, the elongated polyQ tract may prevent the normal folding of the AR proteins, 
allowing its misfolding and aggregation. In fact, HSP release may expose a previously masked 
elongated polyQ causing its aggregation in the cytoplasm or in the nucleus. Several studies pointed 
out that the translocation and accumulation of ARpolyQ into the nucleus may be relevant for its 
toxicity [87–92]. Since BBR is able to reduce the overall accumulation of ARpolyQ in cells, this may 
also prevent the accumulation of misfolded ARpolyQ species inside the nucleus, thus preventing its 
nuclear toxicity. In addition to that, we demonstrated that BBR is also able to induce the degradation 
of other misfolded proteins, such as the 25 kDa C-terminal fragment of TDP-43, the TDP-25, involved 
in sALS (and in line with previous reports [54]), as well as mutant SOD1 causative of some forms of 
fALS. Of note, the effects of BBR on mutant SOD1-G93A may be associated to the antioxidant 
properties of BBR, which is able to maintain the activity of several antioxidant enzymes, including 
SOD1 [93], but it is likely that BBR also enhances the clearance of misfolded fraction of mutant SOD1-
G93A prone to aggregate, thus exerting its neurotoxicity in affected neurons. In this context, the 
action of BBR seems to be rather specific, since we found that the levels of the endogenous SOD1 are 
not affected by BBR treatment, clearly indicating that BBR acts preferentially and specifically on 
misfolded protein clearance. 
Since BBR was already tested in cellular and mouse models of HD, showing efficacy in 
promoting the clearance of mutant HTT by autophagic activation [55], we also evaluate if BBR was 
active in our cellular model of HD, but we did not confirm the data published, an effect possibly 
correlated to the different BBR dose used in our study compared to that previously reported [55] (5 
to 100 μM) that were toxic in our cells. 
Collectively, our data suggest that the neuroprotective properties of BBR in NDs might be 
primarily ascribed by its ability to potentiate intracellular degradative pathways, inducing misfolded 
protein clearance. However, how BBR enhances misfolded protein clearance remains obscure, since 
some reports point to an involvement of autophagy [54,55,60], while others to the UPS system [59,94–
96]. In our case, we found that the enhanced degradation induced by BBR on ARpolyQ in SBMA is 
mainly associated to the UPS rather than to autophagy; additional studies are now in progress in our 
laboratory to fully characterize this mechanism from a molecular point of view. 
Because of the positive effects of BBR in SBMA, we went further, analyzing three BBR 
semisynthetic derivatives, the NAXs compounds, which were designed to improve the activity of 
BBR in some tumors, such as colon, breast and pancreatic cancer. The NAXs are characterized by the 
presence of aromatic groups linked to the C-13 position, in order to allow additional non covalent 
interaction with the molecular targets [72–74,97]. In cancer models, these compounds resulted to be 
more effective than BBR, and represent promising anticancer drugs, while they have never been 
tested for their activity in NDs. Interestingly, we found that all NAXs reduced the number of cells 
bearing intracellular ARpolyQ aggregates, but only NAX014 was able to induce a significant 
clearance of the mutant protein, both in the soluble and in the insoluble forms. In addition, in cellular 
model of fALS expressing SOD1-G93A, all NAXs stimulated the degradation of mutant SOD1 and 
this effect was much more pronounced than that exerted by BBR. Conversely, in our cellular model 
of sALS (GFP-TDP25 expressing cells), only NAX014 exerted effects similar to BBR, while NAX035 
was the unique compound effective in the clearance of mutant huntingtin in HD cell model. 
Moreover, these compounds seem to have a selective activity in response to specific misfolded 
proteins, for example NAX014 is effective on AR.Q46, TDP-25 and mutant SOD1, while it is 
ineffective or even detrimental on mHTT accumulation. This suggests that NAXs might activate 
different cell pathways with different effects in the presence of different type of misfolding proteins. 
Therefore, the chemical modifications to BBR skeleton might be able to induce selectivity on the mode 
of action of BBR, an interesting aspect, even if it remains to be determined whether these differences 
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have to be ascribed to possible modification in their bioavailability or metabolism, as well as to their 
potential direct specific interaction with target misfolded proteins. Further studies aimed to better 
evaluate these mechanisms are in progress in our laboratory. At the same time, studies in animal 
models of NDs are required to determine if the compounds found active in cell models can be 
considered promising approach to ameliorate disease progression in NDs. 
In this work, for the first time it has been demonstrated the beneficial effect of BBR in the 
clearance of ARpolyQ in motoneuronal cells. Although, a detailed mechanism of action has not been 
provided, BBR might be interesting for SBMA. While NAXs have been already tested in different 
types of cancer [72–74,97], this is the first report showing their potential use also in NDs. As 
mentioned above, some NAXs were found to have similar or more potent effects than BBR, but with 
different specific activities depending upon the misfolded protein target evaluated, suggesting that 
these compounds might be selective for mutant proteins. Given the pleiotropic and cell-specific 
effects exerted by BBR, and the different effects observed by NAX treatment on misfolded proteins 
clearance, future perspectives will be focused on unraveling the detailed mechanism of action of BBR 
on misfolded protein clearance, and, moreover, on understanding the different and specific activity 
of NAXs. It is possible that the different NAXs might activate different intracellular pathways leading 
to a selective clearance of misfolded proteins. 
We believe that these data can be extended to other NDs, primarily caused by the formation and 
accumulation of misfolded proteins into specific neuronal populations. Indeed, compounds able to 
enhance misfolded protein clearance result in being very attractive for NDs, complex disorders 
generally characterized by the alteration of multiple intracellular functions and often by a slow 
progression. In this line, the use of natural compounds able to cross the BBB might represent a safe 
and useful treatment alone or in combination with other drugs. 
4. Materials and Methods 
4.1. Chemicals 
Berberine chloride form (B3251), dimethyl sulfoxide (276855), testosterone (86500), Z-Leu-Leu-
Leu-al/MG132 (C2211), 3-methyladenine (M9281), cycloheximide (C4859) were purchased from 
Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). 13-[2-(4-chlorophenyl)ethyl]berberine iodide 
(NAX014), 13-(3,3-diphenylpropyl)berberine chloride (NAX035), and 13-[3,3-bis(4-
methoxyphenyl)propyl]berberine chloride (NAX117) were provided by Naxospharma 
(Naxospharma s.r.l., Novate Milanese, Milan, Italy). MG132, 3-MA, BBR and NAXs were dissolved 
in dimethyl sulfoxide (DMSO), cycloheximide was dissolved in water, and testosterone was 
dissolved in ethanol. 
4.2. Plasmids 
EGFP-N1 plasmid was purchased from Clontech (Takara Bio Inc., Kusatsu, Japan). It was used 
in cotransfection with AR.Q46, pCDNA3-SOD1-G93A and HTT-exon1-73Q for controlling 
transfection efficiency. For AR biochemical analysis in the plasmid encoding for human AR with 46 
polyQ size was used, kindly provided by Prof. M. Marcelli (Baylor College of Medicine, Houston, 
TX, USA [26]. For fluorescence microscopy analysis, the chimeric versions of AR tagged with GFP 
were used. GFP-AR.Q(n) plasmids encode a chimeric green fluorescent protein-AR with 22 or 48 
polyQ stretch, which were kindly provided by Dr. Michael A. Mancini [98]. The pCDNA3-SOD1-
G93A plasmid encoding G93A mutant SOD1 was kindly provided by Dr. C. Bendotti (Mario Negri 
Institute for Pharmacological Research, Milan, Italy). The GFP-TDP-25 encodes GFP protein fused 
with the 25-kDa C-terminal fragment of TARDBP was kindly provided by Prof. L. Petrucelli (Mayo 
Clinic, Jacksonville, FL, USA). The HTT-exon1-73Q plasmid contains the cDNA corresponding to 
exon-1 of HTT encoding the mutant HTT N-terminus (exon-1) with a polyQ of 73 glutamines and it 
was kindly provided by Dr. M. Basso (University of Trento, Trento, Italy). 
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4.3. Cell Cultures and Transfections 
The mouse motor-neuron-like hybrid cell line (NSC34), kindly provided by Dr. N.L. Cashman 
(University of British Columbia, Vancouver, CAN) [99], was maintained in DMEM medium 
supplemented with 5% fetal bovine serum (FBS)(F7524, Sigma-Aldrich), 1 mM L-glutamine 
(ECB3004D, Euroclone, Pero, Italy), and penicillin-streptomycin (penicillin, 31749.04, SERVA 
Electrophoresis GmbH, Heidelberg, Germany; streptomycin, 35500.01, SERVA Electrophoresis 
GmbH), at 37 °C in 5% CO2. For experiments involving testosterone treatment, a dextran-treated 
charcoal-stripped FBS was used to selectively remove hormones [100,101]. For the expression of the 
exogenous mutant proteins, NSC34 cells were transiently transfected with 0.7 μg of plasmid DNA 
using transferrin (T8150, Sigma-Aldrich) in conjunction with Lipofectamine reagent (18324012, 
Thermo Scientific Life Sciences Research, Waltham, MA, USA) to improve transfection efficiency. 
4.4. MTT Assay 
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) (M5655, Sigma-Aldrich) 
assay was performed to test cellular metabolic activity, and cell viability. NSC34 were seeded at 
45,000 cell/well in 24-well plates, treated with different doses of BBR or NAXs as described in Figure 
legends. After 48 h of treatment, the medium was removed, cells were incubated for 30 min with 300 
μL of MTT at 37 °C, then 500 μL of 2-propanol were added to each well as dissolving solvent. 
Absorbance was measured at OD = 570 nm with an Enspire® Multimode plate reader (PerkinElmer, 
Waltham, MA, USA). The experiments were performed with six independent samples (n = 6). 
4.5. Western Blot and Filter Retardation Assay 
For WB and FRA, cells were seeded at 90,000 cells/well in a 12-well plate, and transfected/treated 
as described in the text. Forty-eight hours after transfection, the cells were collected and centrifuged 
at 500 g for 5 min at 4 °C. The pellets were lysed in PBS solution supplemented with protease 
inhibitors (Sigma-Aldrich, P8340) using slight sonication. Protein extracts were quantified with the 
bicinchoninic acid method (EMP014500, Euroclone, EMP014500, Pero, Italy). For WB analysis, 20 μg 
of proteins were loaded on 12% SDS-polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membrane by the Trans-Blot® Turbo™ transfer system (Bio-Rad Laboratories, 1704150, 
(Bio-Rad, Hercules, CA, USA). FRA is a technique routinely used in our laboratory to measure the 
high-molecular-weight species or insoluble proteins. Sample filtration is based on the membrane 
composition (cellulose acetate membrane does not have affinity for proteins) and porosity. Only 
insoluble proteins remain entrapped on the membrane [35,36,43,102]. For FRA, 3 μg of proteins were 
loaded and filtered on cellulose acetate in a slot-blot apparatus (1703938, Bio-Rad Laboratories, 
1703938). FRA membranes were processed following the WB protocol. The membranes were 
incubated for 1 h in blocking solution (1X-TBST with 5% w/v nonfat dried milk), followed by 
overnight incubation with diluted primary antibody in blocking solution. The following primary 
antibodies were used: anti-AR (H280; Santa Cruz Biotechnology, Dallas, TX, USA), (sc-13062; 1:1000), 
anti-GFP for TDP (Abcam, Cambridge, UK) (AB1218; 1:2000), anti SOD1 (Enzo Life Sciences, 
Farmingdale, NY, USA) (ADI-SOD-100, 1:1000), anti-HTT (Sigma-Aldrich), (MAB2166, 1:2000), anti-
GAPDH (FL-335; Santa-Cruz Biotechnology), (sc-25778; 1:3000). After incubation, the blots were 
washed and incubated for 1 h with peroxidase-conjugated secondary antibodies (Jackson 
Immunoresearch Laboratories, West Grove, PA, USA) (111-035-003 goat antirabbit; 115-035-003 goat 
antimouse; 1:5000). Chemiluminescent substrate detection was performed using ClarityTM ECL 
Western blotting substrate (1705060, Bio-Rad Laboratories, 1705060) and Chemidoc XRS System 
(1708265, Bio-Rad). Quantification analysis was performed using Image Lab Software, version 5.2.1 
(Bio-Rad). For WB data quantification and normalization, the band intensity of the target protein was 
divided by the intensity of the loading control protein, GAPDH. Three independent biological 
samples for each condition were analyzed and quantified. Then, we performed a comparative 
analysis of relative target protein levels across sample expressed as fold difference compared to the 
mean value of lane 1 intensity (normalized density of each line divided by the mean value of 
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normalized density of lane 1 samples). 
4.6. Fluorescence Microscopy Analysis 
For fluorescence microscopy analysis, we used the chimeric version of AR, the GFP-ARQn 
plasmids. The cells were seeded at 35,000 cells/well in 24-well plates on 13-mm coverslips, transfected 
and treated as described in figure legends. The cells were fixed with 4% paraformaldehyde in PBS 
and the nuclei were stained with DAPI (1:10,000 in PBS). Coverslips were mounted onto slides with 
Mowiol® 4-88 (475904, Merck-Millipore, Burlington, MA, USA) and analyzed with an Axiovert 200 
microscope (Zeiss, Oberkochen, Germany) equipped with a Photometric Cool-Snap CCD camera 
(Ropper Scientific, Trenton, NJ, USA). The percentage of cells with aggregates was calculated by 
dividing the number of cells with aggregates by the total number of transfected cells and was 
performed by manual counting of three fields per sample (n = 3), using PL10X/20 eyepiece with 
graticules. The fields were randomly selected by a blinded observer. Representative images of 
fluorescence microscopy analysis were acquired using Zeiss LSM900 laser scan microscope and 
analyzed with Zen software (Zeiss). 
4.7. Statistical Analysis 
The data are presented as mean ± standard deviation. Statistical analysis has been performed 
using PRISM (version 7) software (GraphPad Software, San Diego, CA, USA). Analysis of variance 
(ANOVA) was done to compare three or more groups: one-way ANOVA for single independent 
variable, two-way ANOVA for two independent variables. p value <0.05 was considered statistically 
significant. A post hoc test was performed (see figure legends for details). 
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Figure S1. NAXs molecular structure and effects of NAXs on cell viability. (A) Molecular structures of BBR, 
NAX014, NAX035, NAX117. (B-D) MTT cell viability assay was performed on NSC34 cells treated with NAX014 
(B), NAX035 (C) and NAX117 (D) at different concentrations for 48 h (*** p < 0.001, one-way ANOVA, followed 
by Tukey’s test). 
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